The corporate venture capital fund of a larger firm based in the Western US is currently investing from its second fund of $100M. The arm invests in early-stage biotechnology companies focusing on discovering and developing human therapeutics primarily in the areas of the current therapeutic interest to its parent company. The firm typically invests (equity) $2M to $3M per round with $10M reserved for follow-on investments. The firm seeks companies that are based in the US and Europe. They also seek to make 2 or 3 allocations in the next 6-9 months.
The venture arm seeks early-stage companies developing human therapeutics. The firm is seeking companies with products in pre-clinical to phase IIa. The firm’s therapeutic areas of focus are: Cardiovascular (Acute Coronary Syndromes, Dyslipidemia, Heart Failure); Hematology (Anemia, Neutropenia, Stem Cell Mobilization); Inflammation (Asthma, Bowel Disease, Multiple Sclerosis, Osteoarthritis, Psoriasis, Rheumatoid arthritis, Systemic Lupus Erythematosus); Metabolic Disorders (Diabetes, Osteoporosis); Nephrology (Hyperparathyroidism, Renal Failure); Neuroscience (Alzheimer’s Disease, Cognition, Pain-Neuropathic & Inflammatory, Parkinson’s Disease, Schizophrenia); and Oncology. The firm is also interested in drug delivery therapeutics.
The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.
Next Phase Newsletter 